OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 5, pp. 1435-1442
Closed Access | Times Cited: 17
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 5, pp. 1435-1442
Closed Access | Times Cited: 17
Showing 17 citing articles:
A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 44
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 44
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
Edoardo Caronna, Victor J Gallardo, Gabriella Egeo, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024), pp. jnnp-333295
Closed Access | Times Cited: 18
Edoardo Caronna, Victor J Gallardo, Gabriella Egeo, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024), pp. jnnp-333295
Closed Access | Times Cited: 18
Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options
Emmanouil V. Dermitzakis, Andreas A. Argyriou, Konstantinos Bilias, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 10, pp. 2768-2768
Open Access | Times Cited: 4
Emmanouil V. Dermitzakis, Andreas A. Argyriou, Konstantinos Bilias, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 10, pp. 2768-2768
Open Access | Times Cited: 4
Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
Brain Sciences (2024) Vol. 14, Iss. 9, pp. 948-948
Open Access | Times Cited: 4
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
Brain Sciences (2024) Vol. 14, Iss. 9, pp. 948-948
Open Access | Times Cited: 4
Switching between anti-cgrp monoclonal antibodies in migraine prophylaxis
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3218-3218
Open Access | Times Cited: 10
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3218-3218
Open Access | Times Cited: 10
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine
Emmanouil V. Dermitzakis, Michail Vikelis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 386-386
Open Access | Times Cited: 3
Emmanouil V. Dermitzakis, Michail Vikelis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 386-386
Open Access | Times Cited: 3
Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications
Aynur Özge, Betül Baykan, Şebnem Bıçakçı, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 3
Aynur Özge, Betül Baykan, Şebnem Bıçakçı, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 3
Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
A. López-Bravo, Ane Mínguez‐Olaondo, C. Nieves-Castellanos, et al.
Headache The Journal of Head and Face Pain (2025)
Closed Access
A. López-Bravo, Ane Mínguez‐Olaondo, C. Nieves-Castellanos, et al.
Headache The Journal of Head and Face Pain (2025)
Closed Access
Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
Michail Vikelis, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4526-4526
Open Access | Times Cited: 9
Michail Vikelis, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4526-4526
Open Access | Times Cited: 9
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study
Valeria Caponnetto, Antonio Russo, Marcello Silvestro, et al.
CNS Drugs (2023) Vol. 37, Iss. 12, pp. 1069-1080
Open Access | Times Cited: 8
Valeria Caponnetto, Antonio Russo, Marcello Silvestro, et al.
CNS Drugs (2023) Vol. 37, Iss. 12, pp. 1069-1080
Open Access | Times Cited: 8
Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García-Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García-Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: results of an Australian multicentre study
Jason C. Ray, Linda J. Dalic, Josephine Baker, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 1, pp. e000547-e000547
Open Access | Times Cited: 2
Jason C. Ray, Linda J. Dalic, Josephine Baker, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 1, pp. e000547-e000547
Open Access | Times Cited: 2
Cgrp Monoclonal Antibodies: Key Lessons from Real World Evidence
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
(2024)
Open Access | Times Cited: 2
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
(2024)
Open Access | Times Cited: 2
Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study
Laura Zanandrea, Roberta Messina, Ilaria Cetta, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 12
Open Access | Times Cited: 1
Laura Zanandrea, Roberta Messina, Ilaria Cetta, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 12
Open Access | Times Cited: 1
Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 11, pp. 1119-1126
Closed Access
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 11, pp. 1119-1126
Closed Access
